Sélectionner la langue
CD79B
CD79B Informations sur la molécule
| Nom anglais | B-cell antigen receptor complex-associated protein beta chain | Nombre de médicaments commercialisés | 1 |
| Nombre de médicaments cliniques | 9 | Alias de la cible | B-Cell Antigen Receptor Complex-Associated Protein Beta Chain，B29，Immunoglobulin-associated B29 protein，Ig-beta，B-cell-specific glycoprotein B29，CD79B，CD79b Molecule，CD79b Molecule， Immunoglobulin-Associated Beta，IGB，CD79B Antigen (Immunoglobulin-Associated Beta)，CD79b Antigen，AGM6 |
| Phase de R&D la plus avancée | Approved | ||
| Nom anglais | B-cell antigen receptor complex-associated protein beta chain |
| Alias de la cible | B-Cell Antigen Receptor Complex-Associated Protein Beta Chain，B29，Immunoglobulin-associated B29 protein，Ig-beta，B-cell-specific glycoprotein B29，CD79B，CD79b Molecule，CD79b Molecule， Immunoglobulin-Associated Beta，IGB，CD79B Antigen (Immunoglobulin-Associated Beta)，CD79b Antigen，AGM6 |
| Nombre de médicaments commercialisés | 1 |
| Nombre de médicaments cliniques | 9 |
| Phase de R&D la plus avancée | Approved |
CD79B Liste de produits
- Attribut
Protein (9)Cell (1)
- Bibliothèque de produits
En ligne (10)
- Espèces
Human (5)Mouse (3)Cynomolgus (2)
- Étiquette
Fc Tag (2)His Tag (4)His Tag & Avi Tag (3)- (1)
- Marqueur
Unconjugated (5)Biotin-labeled (3)PE Labeled (1)- (1)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
HOT CDB-H5259 |  Human | HEK293 | Human CD79B Protein, Fc Tag, low endotoxin |  |  |  |  Ajouter au panier |
HOT CDB-H52H3 | Human | HEK293 | Human CD79B Protein, His Tag, low endotoxin (MALS verified) |  | | | Ajouter au panier |
HOT CDB-H82E3 | Human | HEK293 | Biotinylated Human CD79B Protein, His,Avitag™ (MALS verified) |  | | | Ajouter au panier |
HOT CDB-HP2H6 | Human | HEK293 | PE-Labeled Human CD79B Protein, His Tag (Site-specific conjugation) |  | Ajouter au panier | ||
| Human | CHO | CHO/Human CD79B Stable Cell Line |  | Ajouter au panier | |||
 Mouse | HEK293 | Mouse CD79B Protein, Fc Tag (MALS verified) |  | | Ajouter au panier | ||
| Mouse | HEK293 | Mouse CD79B Protein, His Tag, low endotoxin (MALS verified) |  | | Ajouter au panier | ||
| Mouse | HEK293 | Biotinylated Mouse CD79B Protein, His,Avitag™ (MALS verified) |  | | Ajouter au panier | ||
 Cynomolgus | HEK293 | Cynomolgus CD79B Protein, His Tag (MALS verified) |  | | | Ajouter au panier | |
| Cynomolgus | HEK293 | Biotinylated Cynomolgus CD79B Protein, His,Avitag™ |  | | Ajouter au panier |
Quantité totale10
- 1
CD79BContexte de la molécule
B-cell antigen receptor complex-associated protein beta chain (CD79b) is also known as B-cell-specific glycoprotein B29, Ig-beta,Immunoglobulin-associated B29 protein, B29 and IGB, which is a single-pass type I membrane protein containing one Ig-like V-type ( immunoglobulin-like ) domain and one ITAM domain.CD79b is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR).CD79b can enhance phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Defects in CD79b are the cause of agammaglobulinemia type 6 (AGM6) that is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development.
CD79BAlias de la molécule
CD79b,B29,IGB,Ig-beta
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| SHR-A1912 | SHR-A1912 | Phase 3 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse | Details |
| CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR CD19/79b | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, B-Cell; Lymphoma, B-Cell | Details |
| TolDCB29 | Phase 2 Clinical | Umc Utrecht | Arthritis, Rheumatoid | Details | |
| JNJ-95566692 | JNJ-95566692 | Phase 1 Clinical | Janssen Research & Development Llc | Lymphoma, Non-Hodgkin | Details |
| LTZ-301 | LTZ-301 | Phase 1 Clinical | LTZ Therapeutics Inc | Autoimmune Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details |
| CD79b-19 CAR T Cells Therapy (Massachusetts General Hospital) | Phase 1 Clinical | Massachusetts General Hospital | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Primary mediastinal B cell lymphoma | Details | |
| Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy（MD Anderson Cancer Center） | JV-213 | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Lymphoma; Lymphoma, B-Cell | Details |
| NBT-508 | Phase 1 Clinical | Newbio Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
| CD79b CAR-T cell therapy (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd, Zhejiang University | Leukemia, Biphenotypic, Acute; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Polatuzumab vedotin | RO-5541077-000; FCU-2711; DCDS-4501A; RG-7596; RO-5541077 | Approved | Genentech Inc, Seagen Inc | Polivy, 优罗华 | United States | Lymphoma, Large B-Cell, Diffuse | Genentech Inc | 2019-06-10 | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments commercialisés
- Informations sur les médicaments cliniques
Partager vers :